Pharma takes the largest share at 29.1%, while health care equipment and biotech round off the top three spots. Of these, Johnson & Johnson occupies the top position with 9% allocation. This ETF tracks the MSCI US Investable Market Health Care 25/50 Index and holds 391 stocks in its basket. It trades in a good volume of around 104,000 shares a day and has a Zacks ETF Rank #2 with a Medium risk outlook. The product has amassed nearly $2.2 billion in its asset base and charges 43 bps in annual fees. In terms of industrial exposure, pharma takes the top spot at 30.2%, followed by health care equipment (23.7%) and biotech (17.3%). Here again, Johnson & Johnson dominates the fund’s returns with 9.5% of the total assets. This fund offers exposure to 130 securities by tracking the Dow Jones U.S. It has a Zacks ETF Rank #2 (Buy) with a Medium risk outlook (read: 4 ETFs to Bet on Global Aging Population). Pharma accounts for 31.6% share from a sector look, while health care equipment and supplies, health care providers and services, and biotech have double-digit exposure each. In total, the fund holds 62 securities in its basket, with JNJ taking the top spot at 10.3% of the assets. This fund manages nearly $17.8 billion in its asset base and trades in heavy volume of around 11.2 million shares. The most popular health care ETF, XLV follows the Health Care Select Sector Index. The product has accumulated $5 million in its asset base and trades in a meager volume of 3,000 shares per day on average. Holding 214 stocks in its basket, JNJ is the top firm with 11.2% allocation. This actively managed ETF employs data science techniques to identify companies with exposure to the innovative health care sector. The fund has a Zacks ETF Rank #3 (Hold) with a High risk outlook (read: AbbVie to Buy Allergan: Prescribed ETFs). Volume is lower as it exchanges about 11,000 shares a day.
The product has $295 million in AUM and charges 43 bps in fees and expenses. Of these, Johnson and Johnson takes the second spot, accounting for 21.2% share. This ETF provides exposure to 43 companies that manufacture prescription or over-the-counter drugs or vaccines by tracking the Dow Jones U.S. Below we have highlighted them (see: all the Healthcare ETFs here). Given this, investors should closely watch the movement of the stock and keep a close eye on ETFs having double-digit allocation to this diversified drug maker. Additionally, Johnson & Johnson belongs to a top-ranked Zacks industry Rank (top 11%), suggesting smooth trading in the days ahead. This sent shares of JNJ down 1.6% despite the strong results.Ĭurrently, the stock has a Zacks Rank #2 (Buy) and a VGM Score of A. However, the company warned competition from generics and biosimilars that could impact its third-quarter results. It reaffirmed its earnings per share guidance of $8.53-$8.63. Revenues fell 1.3% year over year to $20.56 billion but edged past the Zacks Consensus Estimate of $20.32 billion (read: ETFs to Shine as Trump Tosses Drug Rebate Curb Plan).įor 2019, Johnson & Johnson raised its sales forecast to $80.8-$81.6 billion from $80.4-$81.2 billion on robust demand for its cancer drugs. It also raised its guidance for full-year sales growth.Įarnings per share came in at $2.58, 16 cents ahead of the Zacks Consensus Estimate and 22.9% higher than the year-ago quarter. The world's biggest health care products maker continued its long streak of earnings beat and also outpaced revenue estimates. Johnson & Johnson JNJ set the ball rolling for pharma earnings when it reported second-quarter results on Jul 16, before the opening bell.